Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (Q40070782)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Pier Francesco Ferrucci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Jacopo Pigozzo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michele Del Vecchio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Massimo Guidoboni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Paola Queirolo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Francesco Spagnolo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sara Gandini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Diana Giannarelli

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Chiara Martinoli

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

G C Antonini Cappellini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

P Savoia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Mandalà

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

E Simeone

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Valpione

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Altomonte

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

E Cocorocchio

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

P A Ascierto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

22 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

732-738

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26802161%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Immunomonitoring and prognostic relevance of neutrophils in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW016